Twist Bioscience IPO

10/30/2018

IPO

$70,000,000

Approximately $15 million to $20 million to improve and update our platform and core technologies by investing in equipment, expanding our research and development capabilities and establishing new (and scalable) operation facilities; approximately $15 million to $18 million to expand our sales and marketing capabilities in the U.S., Europe and Asia, including approximately $2 million to $3 million to establish our sales and marketing capabilities in China; approximately $12 million to $14 million to continue to expand in the pharmaceutical biologics drug discovery and DNA data storage markets; approximately $5 million to $10 million to establish our operations in China; and any proceeds not applied to the foregoing will be used for working capital and general corporate purposes.

Publicly-held

Biopharmaceutical

455 Mission Bay Blvd South
San Francisco, CA 94158
USA

Undisclosed

At Twist Bioscience (Nasdaq: TWST), our expertise is accelerating science and innovation by leveraging the power of scale. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries.